Trial reportArthritis & rheumatology (Hoboken, N.J.)2026
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis.
Trial report in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advances in the treatment of eosinophilic granulomatosis with polyangiitis.Nature reviews. Rheumatology · 2026Review
- The Use of Biological Therapies in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Current State of Knowledge.Journal of clinical medicine · 2026Review
- Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.Frontiers in immunology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveThe phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab-treated patients achieved complete withdrawal of oral glucocorticoids (OGCs). The objectives of this post hoc analyses are to further elucidate the efficacy of benralizumab and mepolizumab in facilitating reductions in OGCs through investigating timings and sustainability of reducing OGCs as well as the cumulative use of OGCs.
methodsAdults with EGPA requiring ≥7.5 mg/day OGC with or without immunosuppressive therapy were randomized to benralizumab 30 mg (n = 70) or mepolizumab 300 mg (n = 70) subcutaneously every 4 weeks for 52 weeks. Investigators tapered OGCs for patients with stable EGPA based on clinical judgment. Reductions in OGC use (to ≤4 mg/day, by ≥50%, or complete withdrawal) were considered sustained if achieved by week 40 and maintained through week 52.
resultsThe 12-month cumulative dose of OGC was approximately 1,800 mg in both groups. At weeks 49 to 52, the median OGC dose was 1.16 (minimum-maximum 0.0-16.6) and 3.00 (minimum-maximum 0.0-25.7) mg/day for benralizumab and mepolizumab, respectively. Time to first or sustained OGC reduction to ≤4 mg/day or by ≥50% and accrued OGC-free duration were similar between groups. More benralizumab- than mepolizumab-treated patients completely withdrew OGCs (33 of 70 vs 20 of 70; hazard ratio [HR] for the time to the first complete withdrawal 1.84 [95% confidence interval [CI] 1.06-3.27]; unstratified log-rank test P = 0.0291) and sustained complete withdrawal (17 of 70 vs 7 of 70; HR for time to reduction 2.97 [95% CI 1.26-7.77]; unstratified log-rank test P = 0.0268). In both groups, complete OGC withdrawal was similar across patient subgroups, including by antineutrophilic cytoplasmic antibody status and immunosuppressive use.
conclusionTargeting the interleukin-5 receptor with benralizumab or circulating interleukin-5 with mepolizumab are effective OGC-sparing strategies in patients with EGPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.